Arthritis victims seek pain relief from other sources.

Arthritis sufferers seek pain relief from natural products now that Vioxx has been removed from markets worldwide after a study found that long-term users face increased risks for stroke and heart attack

(PRWEB) October 6, 2004 -- Merck & Cos worldwide withdrawal of its COX-2 medicine Vioxx has brought huge opportunity to Swiss Medica (http://www.swissmedica.com/)." This announcement came from Chief Executive Raghu Kilambi shortly after he learned about Vioxx. "Our pain relief product that treats arthritis (http://www.024zone.com/) may find a much larger market share, now that thousands of people with arthritis (http://www.024zone.com/) are searching for an alternative to Vioxx." Kilambi went on, The O24 Essential Oil Pain Neutralizer (http://www.024zone.com/) now celebrates its 10th Anniversary as a safe pain relief alternative to the numerous pills hoping to provide solutions to rheumatoid arthritis and similar ailments."

In September, the O24 Arthritis Relief Solution (http://www.024zone.com/) celebrated its 2nd anniversary of having received U.S. Patent Number 6,444,238 entitled A pain relief composition and a method of relieving pain in a human body." The US Patent specifically notes: The pain relief composition of the present invention is formulated from organically derived essential oils. As such, the pain relief composition provides consumers with a technique to reduce the level of pain while not using artificial, man-made compositions. The organically-derived nature of the composition of the present invention has substantial value to those individuals who desire to reduce pain without using artificial, man-made compositions."

Recently, O24 inventor, Richard Weise announced, People, who have been using this product for ten years, use just this product and nothing else. A lot of people over-medicate for their chronic pain and arthritis. In some cases, O24 (http://www.024zone.com/) replaces the use of pharmaceutical products altogether. Some of the arthritis patients use it three to four times a day." Kilambi concluded, Folks with arthritis (http://www.024zone.com/) are looking for pain relief. That is the bottom line. Our pain relief products have a ten year track record for providing pain relief to people all over the world. Our products are natural and safe, and they work."

About Swiss Medica Inc.

Swiss Medica (http://www.swissmedica.com/) commercializes proprietary bioscience products that relieve chronic ailments, such as arthritis. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medicas (http://www.swissmedica.com/) mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medicas products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medicas periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Investor Relations Contact:

Current Capital (http://www.currentcapital.com/)

Robert Kennedy, President

John Robinson

(877) 859 5200

# # #


Contact Information
Paul Ford
MEDIARIGHT
http://www.mediaright.biz
435-229-0991

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy